1,730 research outputs found
Globalization of Distinguished Supercuspidal Representations of GL(n)
No full textAn irreducible supercuspidal representation of = GL(n, ), where is a nonarchimedean local field of characteristic zero, is said to be “distinguished” by a subgroup of and a quasicharacter of if Hom(, ) ≠ 0. There is a suitable global analogue of this notion for an irreducible, automorphic, cuspidal representation associated to GL(n). Under certain general hypotheses, it is shown in this paper that every distinguished, irreducible, supercuspidal representation may be realized as a local component of a distinguished, irreducible automorphic, cuspidal representation. Applications to the theory of distinguished supercuspidal representations are provided
Restriction of Representations of GL (n + 1, ℂ) to GL (n, ℂ) and Action of the Lie Overalgebra
No full textConsider a restriction of an irreducible finite dimensional holomorphic representation of GL(n+1,C) to the subgroup GL(n,C). We write explicitly formulas for generators of the Lie algebra gl(n+1) in the direct sum of representations of GL(n,C). Nontrivial generators act as differential-difference operators, the differential part has order n − 1, the difference part acts on the space of parameters (highest weights) of representations. We also formulate a conjecture about unitary principal series of GL(n,C).© The Author(s) 201
The Balanced Voronoi Formulas for
No full textAbstract
In this article, we show how the Voronoi summation formula of [13] can be rewritten to incorporate hyper-Kloosterman sums of various dimensions on both sides. This generalizes a formula for with ordinary Kloosterman sums on both sides that was used in [1] to prove nonvanishing of GL(4) -functions by GL(2)-twists, and later by the second-named author in [16].</jats:p
Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease - A randomized, controlled trial
No full textBackground: The effectiveness of oral propafenone in converting recent-onset atrial fibrillation to sinus rhythm has been established by controlled trials. However, it is not clear whether the effectiveness of propafenone is affected by the presence or absence of underlying heart disease. Objectives: To investigate the safety and effectiveness of oral propafenone and the role of underlying heart disease. Design: Randomized, single-blind, controlled study. Setting: 3 teaching hospitals. Patients: 240 hospitalized patients with recent-onset atrial fibrillation. Intervention: Propafenone (one 600-mg oral dose) or placebo. Measurements: Conversion rates at 3 and 8 hours. Results: Propafenone was more effective than placebo for converting atrial fibrillation to sinus rhythm at 3 hours: Fifty-four of 119 patients (45%) receiving propafenone and 22 of 121 patients (18%) receiving placebo had conversion (P < 0.001). It was also more effective at 8 hours: Ninety-one of 119 patients (76%) receiving propafenone and 45 of 121 patients (37%) receiving placebo had con version (P < 0.001). Subgroup analysis showed that among patients without heart disease, 78% of those receiving propafenone and 56% of those receiving placebo converted to sinus rhythm within 8 hours (P = 0.02). In those with hypertension, the rate was 70% for those receiving propafenone and 27% for those receiving placebo (P < 0.001); in patients with structural heart disease, the rate was 81% for those receiving propafenone and 17% for those receiving placebo (P < 0.001). Conclusions: Oral loading of propafenone was more effective than placebo for conversion to sinus rhythm with in 8 hours and had a favorable safety profile. The rate of spontaneous conversion to sinus rhythm was higher in patients without structural heart disease; this finding has important implications for the assessment of drug effectiveness in recent-onset atrial fibrillation
Regular ventricular rhythms before conversion ofrecent onset atrial fibrillation to sinus rhythm.
No full textThe incidence of fast atrial tachycardias with regular ventricular rhythm was assessed in a population of 243 patients with recent onset ( 175 beats/min with 1:1 AV conduction ensued in 4 cases: 2 treated with flecainide and 2 treated with placebo; in the other cases 2:1 AV conduction was observed. Widening of QRS during regular tachycardia was observed in 4 patients; 3 who received propafenone and 1 who received flecainide. Conversion to SR within 4 hours was achieved in 55/92 (60%) patients treated with propafenone, 20/34 (59%) patients treated with flecainide, 7/25 (28%) patients treated with digoxin, and 19/92 (20%) treated with placebo (P < 0.001 propafenone vs placebo and flecainide vs placebo; P < 0.05 propafenone vs digoxin and flecainide vs digoxin). Periods of regular tachycardia are expected in recent onset AF and may not necessarily represent a proarrhythmic effect of Class 1C drugs, rather than mark the transition from AF to SR. Class 1C agents are probably responsible for widening of the QRS complex seen during these tachycardias. Propafenone and flecainide appear equally effective in converting recent onset AF
Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens
No full textA population of 105 patients with recent onset (<72 h) atrial fibrillation was randomly treated with propafenone as a single oral loading dose of 450 mg (Regimen A) or 600 mg (Regimen B) or with placebo. A 24-h Holter was performed. Criteria of efficacy were conversion to sinus rhythm at 2, 4 and 8 h compared to placebo and also significant reduction of mean ventricular rate in persistent atrial fibrillation. After 2 h, regimen B was more effective than either regimen A (43% vs. 8%; p=0.001) or placebo (11%; p=0.004). At 4 h, both the active treatments were more effective than placebo (17% vs. 46% regimen A and 57% vs. regimen B; p<0.04 and p<0.001, respectively). Sinus rhythm resumed within 24 h in 71%, 80% and 69% of the patients with regimen A, B and placebo, respectively (p=not significant): The mean ventricular rate reduction after 1 h was 8%, 11% and 4% for regimen A, B and placebo, respectively (p<0.005 vs. regimen B), and 17%, 25% and 6% respectively (p<0.001 placebo vs. regimen A and B, p<0.05 regimen B vs. A) at 2 h. No major adverse effect occurred. Atrial flutter with 1:1 atrioventricular conduction ensued only in one case who received placebo. Propafenone acute oral administration is more effective than placebo in rapidly converting recent-onset atrial fibrillation to sinus rhythm and may be the treatment of choice in this setting limiting hospitalization and contributing to improved quality of life. Copyright (C) 1997 Elsevier Science Ireland Ltd
Bethe Vectors for Composite Models with gl(2|1) and gl(1|2) Supersymmetry
No full textSupersymmetric composite generalized quantum integrable models solvable by the algebraic Bethe ansatz are studied. Using a coproduct in the bialgebra of monodromy matrix elements and their action on Bethe vectors, formulas for Bethe vectors in the composite models with supersymmetry based on the super-Yangians Y[gl(2|1)] and Y[gl(1|2)] are derived.The author wants to express his gratitude to N.A. Slavnov for the proposal to investigate this
topic and discussions. He thanks also to S. Pakuliak for discussions and to A.P. Isaev and
C. Burd´ık for their support. The work of the author has been supported by the Grant Agency ˇ
of the Czech Technical University in Prague, grant No. SGS15/215/OHK4/3T/14, and by the
Grant of the Plenipotentiary of the Czech Republic at JINR, Dubna
Combinatorial results on (1,2,1,2)-avoiding -orbit closures on
No full text35 pages, 18 figuresInternational audienceUsing recent results of the second author which explicitly identify the "-avoiding" -orbit closures on the flag manifold as certain Richardson varieties, we give combinatorial criteria for determining smoothness, lci-ness, and Gorensteinness of such orbit closures. (In the case of smoothness, this gives a new proof of a theorem of W.M. McGovern.) Going a step further, we also describe a straightforward way to compute the singular locus, the non-lci locus, and the non-Gorenstein locus of any such orbit closure. We then describe a manifestly positive combinatorial formula for the Kazhdan-Lusztig-Vogan polynomial in the case where corresponds to the trivial local system on a -avoiding orbit closure and corresponds to the trivial local system on any orbit contained in . This combines the aforementioned result of the second author, results of A. Knutson, the first author, and A. Yong, and a formula of Lascoux and Sch\"{u}tzenberger which computes the ordinary (type ) Kazhdan-Lusztig polynomial whenever is cograssmannian
- …
